title: Effects of early and late antihypertensive treatment on extracellular matrix proteins and mononuclear cells in uninephrectomized SHR.
abstract: The efficacy of an early and late treatment with the angiotensin converting enzyme inhibitor lisinopril or the angiotensin II receptor blocker ICI D8731 was investigated in uninephrectomized spontaneously hypertensive rats (SHR). Rats that underwent uninephrectomy (UNX) at six weeks of age were randomly assigned to receive no treatment, lisinopril shortly after UNX, lisinopril starting 16 weeks after UNX, ICI D8731 shortly after UNX, and ICI D8731 starting 16 weeks after UNX. Blood pressure was normalized with both treatments. After six months inulin clearance was not significant different, while proteinuria and prevalence of interstitial fibrosis were significantly reduced in all treatment groups. Immunohistochemical studies revealed an interstitial, periglomerular and perivascular increase of extracellular matrix proteins in all rats, but a markedly reduced expression of collagen I, IV and fibronectin after early and late treatment compared to untreated controls. We found a significant reduction of infiltrating macrophages and T-lymphocytes in all treated animals compared to untreated controls after 2, 4 and 6 months. Especially early treatment was associated with lower numbers of infiltrating cells. Both treatments reduced proliferation of tubular and interstitial cells. There were no striking differences with regard to nephroprotection between the ACE inhibitor and angiotensin II receptor blocker. These findings show that both treatments have beneficial effects on kidney structure and function. They suggest that both ACE inhibition and angiotensin II blockade decrease renal cell proliferation and suppress the infiltration of mononuclear cells that may trigger expression of extracellular matrix proteins and progressive nephrosclerosis.
authors.affiliation: Medical Clinic IV, Division of Nephrology, University of Frankfurt, Frankfurt am Main, Germany.
authors.forename: H
authors.initials: H
authors.lastname: Geiger
authors.forename: W
authors.initials: W
authors.lastname: Fierlbeck
authors.forename: M
authors.initials: M
authors.lastname: Mai
authors.forename: H
authors.initials: H
authors.lastname: Ruchti
authors.forename: V
authors.initials: V
authors.lastname: Schönfeld
authors.forename: J
authors.initials: J
authors.lastname: Dämmrich
authors.forename: C
authors.initials: C
authors.lastname: Hugo
authors.forename: H H
authors.initials: HH
authors.lastname: Neumayer
mesh_terms: D057911:Angiotensin Receptor Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000008:administration & dosage; D000818:Animals; D000959:Antihypertensive Agents / Q000008:administration & dosage*; D001713:Biphenyl Compounds / Q000008:administration & dosage; D002455:Cell Division / Q000187:drug effects; D016326:Extracellular Matrix Proteins / Q000378:metabolism*; D006977:Hypertension, Renal / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D007668:Kidney / Q000187:drug effects* / Q000378:metabolism / Q000473:pathology; D017706:Lisinopril / Q000008:administration & dosage; D009392:Nephrectomy; D018809:Proliferating Cell Nuclear Antigen / Q000378:metabolism; D011804:Quinolines / Q000008:administration & dosage; D051381:Rats; D011918:Rats, Inbred SHR; D013997:Time Factors
chemical_list: D057911:Angiotensin Receptor Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors; D000959:Antihypertensive Agents; D001713:Biphenyl Compounds; D016326:Extracellular Matrix Proteins; D018809:Proliferating Cell Nuclear Antigen; D011804:Quinolines; C081112:ICI D8731; D017706:Lisinopril